Log In Sign up
The largest database of trusted experimental protocols

Msh6 clone grbp p1 2 d4

Manufactured by Bio-Rad
Visit Supplier

MSH6 (clone GRBP.P1/2.D4) is a monoclonal antibody that recognizes the MSH6 protein, which is a component of the DNA mismatch repair system. The antibody can be used for the detection of MSH6 in various applications, such as Western blotting and immunohistochemistry.

Automatically generated - may contain errors

Lab products found in correlation

Pms2 clone a16 4, by BD (2 mentions) Mlh1 clone g168 728, by BD (2 mentions)

2 protocols using msh6 clone grbp p1 2 d4

1

Immunohistochemical Assessment of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
MMR status was assessed by immunohistochemistry (IHC) for MLH1, MSH2, MSH6, and PMS2 proteins using standard protocols [21] (link). Primary monoclonal antibodies were MLH1 (clone G168–728, diluted 1:250; BD Biosciences Pharmingen, San Diego, CA), MSH2 (clone FE11, diluted 1:50; Oncogene Research Products, Cambridge, MA), MSH6 (clone GRBP.P1/2.D4, diluted 1:200; AbD Serotec, Raleigh, NC), and PMS2 (clone A16-4, diluted 1:200; BD Biosciences Pharmingen). Non-neoplastic colonic mucosa and colorectal tumors known to be deficient of MLH1, MSH2, MSH6, and PMS2 were used as external positive and negative controls, respectively. Tumors showing loss of expression in one or more of these proteins were considered dMMR, and those showing normal expression of the proteins were mismatch repair-proficient (pMMR).
Li L., Zhou W., Li Q., Li P., Yang L., Xia X., Yi X, & Wan D. (2020). Tumor-derived mutations in postoperative plasma of colorectal cancer with microsatellite instability. Translational Oncology, 14(1), 100945.
+ Open protocol
+ Expand
2

Immunohistochemical Analysis of MMR Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols
Analysis of IHC expression of MMR proteins was performed by using a
clinically validated standard streptavidin-biotin-peroxidase procedure. Primary
monoclonal antibodies used were MLH1 (clone G168–728, diluted 1:250; BD
Biosciences Pharmingen, San Diego, CA), MSH2 (clone FE11, diluted 1:50; Oncogene
Research Products, Cambridge, MA), MSH6 (clone GRBP.P1/2.D4, diluted 1:200; AbD
Serotec, Raleigh, NC), and PMS2 (clone A16–4, diluted 1:200; BD
Biosciences Pharmingen). Non-neoplastic colonic mucosa and colorectal tumors
known to be deficient of MLH1, MSH2, MSH6, and PMS2 were used as external
positive and negative controls, respectively. Retained expression of each
protein was defined by nuclear IHC reactivity of tumor cells, whereas loss of
expression for each protein was defined by the complete absence of nuclear IHC
reactivity of tumor cells. Tumors were MMR proficient if all four proteins were
expressed (retained) by IHC and MMR deficient (MMR-D) if any of the four
proteins was not expressed (lost) by IHC.
Middha S., Zhang L., Nafa K., Jayakumaran G., Wong D., Kim H.R., Sadowska J., Berger M.F., Delair D.F., Shia J., Stadler Z., Klimstra D.S., Ladanyi M., Zehir A, & Hechtman J.F. (2017). Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. JCO Precision Oncology, 1, PO.17.00084.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!